154 related articles for article (PubMed ID: 8245304)
1. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma.
Tan JK; Ho VC
J Dermatol Surg Oncol; 1993 Nov; 19(11):985-90. PubMed ID: 8245304
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin.
MacGregor AB; Falk RE; Landi S; Ambus U; Samuel ES; Langer B
Can J Surg; 1977 Jan; 20(1):25-30. PubMed ID: 832200
[TBL] [Abstract][Full Text] [Related]
3. Role of bacillus Calmette-Guérin in the treatment of advanced melanoma.
Stewart JH; Levine EA
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1671-6. PubMed ID: 22050015
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant BCG immunotherapy for malignant melanoma.
Paterson AH; Willans DJ; Jerry LM; Hanson J; McPherson TA
Can Med Assoc J; 1984 Oct; 131(7):744-8. PubMed ID: 6383591
[TBL] [Abstract][Full Text] [Related]
5. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.
Livingston PO; Wong GY; Adluri S; Tao Y; Padavan M; Parente R; Hanlon C; Calves MJ; Helling F; Ritter G
J Clin Oncol; 1994 May; 12(5):1036-44. PubMed ID: 8164027
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
[TBL] [Abstract][Full Text] [Related]
7. Oral bacille Calmette Guérin immunostimulation in malignant melanoma.
MacGregor AB; Falk RE; Landi S; Ambus U; Langer B
Surg Gynecol Obstet; 1975 Nov; 141(5):747-54. PubMed ID: 1105837
[TBL] [Abstract][Full Text] [Related]
8. Fatal disseminated bacillus Calmette-Guerin infection and arrested growth of cutaneous malignant melanoma following intralesional immunotherapy.
de la Monte SM; Hutchins GM
Am J Dermatopathol; 1986 Aug; 8(4):331-5. PubMed ID: 3532854
[TBL] [Abstract][Full Text] [Related]
9. Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma.
Lipton A; Harvey HA; Balch CM; Antle CE; Heckard R; Bartolucci AA
J Clin Oncol; 1991 Jul; 9(7):1151-6. PubMed ID: 2045856
[TBL] [Abstract][Full Text] [Related]
10. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
Agarwala SS; Neuberg D; Park Y; Kirkwood JM
Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
[TBL] [Abstract][Full Text] [Related]
11. Clinical and molecular insights into BCG immunotherapy for melanoma.
Kremenovic M; Schenk M; Lee DJ
J Intern Med; 2020 Dec; 288(6):625-640. PubMed ID: 32128919
[TBL] [Abstract][Full Text] [Related]
12. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
Cohen MH; Jessup JM; Felix EL; Weese JL; Herberman RB
Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108
[TBL] [Abstract][Full Text] [Related]
13. BCG immunotherapy in patients with malignant melanoma.
Karakousis CP; Douglass HO; Yeracaris PM; Holyoke ED
Arch Surg; 1976 Jun; 111(6):716-8. PubMed ID: 776125
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.
Sterchi JM; Wells HB; Case LD; Spurr CL; White DR; Richards F; Muss HB; Jackson DV; Stuart JJ; Cooper MR
Cancer; 1985 Feb; 55(4):707-12. PubMed ID: 3967167
[TBL] [Abstract][Full Text] [Related]
15. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
Lieberman R; Wybran J; Epstein W
Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
Henz BM; Macher E; Bröcker EB; Suciu S; Steerenberg PA; Jung E; Rümke P
Dermatology; 1996; 193(2):105-9. PubMed ID: 8884144
[TBL] [Abstract][Full Text] [Related]
17. Re-inventing intratumoral immunotherapy for melanoma.
Triozzi PL; Tuthill RJ; Borden E
Immunotherapy; 2011 May; 3(5):653-71. PubMed ID: 21554094
[TBL] [Abstract][Full Text] [Related]
18. The role of adjuvant therapy in melanoma management.
Barth A; Morton DL
Cancer; 1995 Jan; 75(2 Suppl):726-34. PubMed ID: 7805001
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of Bacillus Calmette-Guérin (percutaneous administration) as surgical adjuvant immunotherapy for patients with stage-II melanoma.
Pinsky CM; Hirshaut Y; Wanebo HJ; Fortner JG; Miké V; Schottenfeld D; Oettgen HF
Ann N Y Acad Sci; 1976; 277(00):187-94. PubMed ID: 1069548
[No Abstract] [Full Text] [Related]
20. Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781).
Czarnetzki BM; Macher E; Suciu S; Thomas D; Steerenberg PA; Rümke P
Eur J Cancer; 1993; 29A(9):1237-42. PubMed ID: 8343260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]